Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 1/2019

18.01.2019 | Review Article

Comparative efficacy of ivabradine versus beta-blockers in patients with mitral stenosis in sinus rhythm: systematic review and meta-analysis

verfasst von: Nashmil Ghadimi, Sara Kaveh, Hossein Shabaninejad, Alaadine Lijassi, Ali Zahed Mehr, Hossein Hosseinifard

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Background Patients with mitral valve stenosis have increased heart rate. HR reduction is known as an important treatment and therapy strategy for patients with mitral valve stenosis. Aim of the review The aim of this systematic review and meta-analysis was to compare the efficacy of ivabradine versus beta-blockers in patients with mitral stenosis in sinus rhythm. Methods Randomized controlled trials were searched in Cochrane Library, PubMed, Web of Science, CRD, Scopus, and Google Scholar with no start time limitation and ending June 2018. Risk of bias across was assessed by the Cochrane Risk of Bias Assessment tool. Fixed effects models were used to combine the results and the mean difference with a 95% confidence interval. This meta-analysis was performed using Meta Package in R software. Results Five studies entered meta-analysis. The total number of patients treated with ivabradine and beta-blockers was 178 and 178 respectively. The results showed that the mean of maximum HR and HR at rest was lower at about 5.03 units and upper 4.32 units respectively with use of ivabradine compared with the use of beta-blockers. These values were statistically significant. Conclusion It seems that the efficacy of ivabradine is good in comparison with betablockers, but it still requires more clinical trials.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat De Santis V, Vitale D, Santoro A, Magliocca A, Porto AG, Nencini C, et al. Ivabradine: potential clinical applications in critically ill patients. Clin Res Cardiol. 2013;102(3):171–8.CrossRef De Santis V, Vitale D, Santoro A, Magliocca A, Porto AG, Nencini C, et al. Ivabradine: potential clinical applications in critically ill patients. Clin Res Cardiol. 2013;102(3):171–8.CrossRef
2.
Zurück zum Zitat Guglin M. Heart rate reduction in heart failure: ivabradine or beta blockers? Heart Fail Rev. 2013;18(4):517–28.CrossRef Guglin M. Heart rate reduction in heart failure: ivabradine or beta blockers? Heart Fail Rev. 2013;18(4):517–28.CrossRef
3.
Zurück zum Zitat Al Zaibag M, Al Kasab S, Ribeiro P, Al Fagih M. Percutaneous double-balloon mitral valvotomy for rheumatic mitral-valve stenosis. Lancet. 1986;327(8484):757–61.CrossRef Al Zaibag M, Al Kasab S, Ribeiro P, Al Fagih M. Percutaneous double-balloon mitral valvotomy for rheumatic mitral-valve stenosis. Lancet. 1986;327(8484):757–61.CrossRef
4.
Zurück zum Zitat Carabello BA. Mitral valve regurgitation. Curr Probl Cardiol. 1998;23(4):197–241.CrossRef Carabello BA. Mitral valve regurgitation. Curr Probl Cardiol. 1998;23(4):197–241.CrossRef
5.
Zurück zum Zitat Sun JP, Felner JM. Mitral Valve Stenosis. Practical Handbook of Echocardiography: 101 Case Studies. 2010:38-41. Sun JP, Felner JM. Mitral Valve Stenosis. Practical Handbook of Echocardiography: 101 Case Studies. 2010:38-41.
6.
Zurück zum Zitat Muhammad F, Nazeer A, Rehman Z. The comparison of effects of ivabradine and atenolol on heart rate and symptoms in patients with mild-to-moderate mitral stenosis. Pak J Med Health Sci. 2016;10(2):345–7. Muhammad F, Nazeer A, Rehman Z. The comparison of effects of ivabradine and atenolol on heart rate and symptoms in patients with mild-to-moderate mitral stenosis. Pak J Med Health Sci. 2016;10(2):345–7.
7.
Zurück zum Zitat Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr., Faxon DP, Freed MD, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2006;48(3):e1–148.CrossRef Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr., Faxon DP, Freed MD, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2006;48(3):e1–148.CrossRef
8.
Zurück zum Zitat Guglin M. Heart rate reduction in heart failure: ivabradine or beta blockers? Heart Fail Rev. 2013;18(4):517–28.CrossRef Guglin M. Heart rate reduction in heart failure: ivabradine or beta blockers? Heart Fail Rev. 2013;18(4):517–28.CrossRef
9.
Zurück zum Zitat Members TF, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, et al. ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003.CrossRef Members TF, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, et al. ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003.CrossRef
10.
Zurück zum Zitat Riccioni G. Ivabradine: the hope for a good treatment of ischemic heart disease. Curr Med Chem. 2013;20(14):1817–23.CrossRef Riccioni G. Ivabradine: the hope for a good treatment of ischemic heart disease. Curr Med Chem. 2013;20(14):1817–23.CrossRef
11.
Zurück zum Zitat Alan S, Ulgen MS, Ozdemir K, Keles T, Toprak N. Reliability and efficacy of metoprolol and diltiazem in patients having mild to moderate mitral stenosis with sinus rhythm. Angiology. 2002;53(5):575–81.CrossRef Alan S, Ulgen MS, Ozdemir K, Keles T, Toprak N. Reliability and efficacy of metoprolol and diltiazem in patients having mild to moderate mitral stenosis with sinus rhythm. Angiology. 2002;53(5):575–81.CrossRef
12.
Zurück zum Zitat Monmeneu JM, Marín FO, Reyes FG, Jordán AT, García MM, Bodí VP, et al. Beta-blockade and exercise capacity in patients with mitral stenosis in sinus rhythm. J Heart Valve Dis. 2002;11(2):199–203. Monmeneu JM, Marín FO, Reyes FG, Jordán AT, García MM, Bodí VP, et al. Beta-blockade and exercise capacity in patients with mitral stenosis in sinus rhythm. J Heart Valve Dis. 2002;11(2):199–203.
13.
Zurück zum Zitat Tardif J-C, Ponikowski P, Kahan T. Efficacy of the I f current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J. 2009;30(5):540–8.CrossRef Tardif J-C, Ponikowski P, Kahan T. Efficacy of the I f current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J. 2009;30(5):540–8.CrossRef
14.
Zurück zum Zitat DiFrancesco D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res. 2006;53(5):399–406.CrossRef DiFrancesco D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res. 2006;53(5):399–406.CrossRef
15.
Zurück zum Zitat De Santis V, Vitale D, Santoro A, Magliocca A, Porto AG, Nencini C, et al. Ivabradine: potential clinical applications in critically ill patients. Clin Res Cardiol. 2013;102(3):171–8.CrossRef De Santis V, Vitale D, Santoro A, Magliocca A, Porto AG, Nencini C, et al. Ivabradine: potential clinical applications in critically ill patients. Clin Res Cardiol. 2013;102(3):171–8.CrossRef
16.
Zurück zum Zitat Fala L. Corlanor (Ivabradine), First HCN Channel Blocker, FDA Approved for the Treatment of Patients with Heart Failure. Am Health Drug Benefits. 2016;9(Spec Feature):56.PubMedPubMedCentral Fala L. Corlanor (Ivabradine), First HCN Channel Blocker, FDA Approved for the Treatment of Patients with Heart Failure. Am Health Drug Benefits. 2016;9(Spec Feature):56.PubMedPubMedCentral
17.
Zurück zum Zitat Speranza L, Franceschelli S, Riccioni G. The biological effects of ivabradine in cardiovascular disease. Molecules. 2012;17(5):4924–35.CrossRef Speranza L, Franceschelli S, Riccioni G. The biological effects of ivabradine in cardiovascular disease. Molecules. 2012;17(5):4924–35.CrossRef
18.
Zurück zum Zitat Urbanek I, Kaczmarek K, Cygankiewicz I, Ptaszynski P. Risk-benefit assessment of ivabradine in the treatment of chronic heart failure. Drug Healthc Patient Saf. 2014;6:47.PubMedPubMedCentral Urbanek I, Kaczmarek K, Cygankiewicz I, Ptaszynski P. Risk-benefit assessment of ivabradine in the treatment of chronic heart failure. Drug Healthc Patient Saf. 2014;6:47.PubMedPubMedCentral
19.
Zurück zum Zitat Werdan K, Perings S, Köster R, Kelm M, Meinertz T, Stöckl G, et al. Effectiveness of ivabradine treatment in different subpopulations with stable angina in clinical practice: a pooled analysis of observational studies. Cardiology. 2016;135(3):141–50.CrossRef Werdan K, Perings S, Köster R, Kelm M, Meinertz T, Stöckl G, et al. Effectiveness of ivabradine treatment in different subpopulations with stable angina in clinical practice: a pooled analysis of observational studies. Cardiology. 2016;135(3):141–50.CrossRef
20.
Zurück zum Zitat Agrawal V, Kumar N, Lohiya B, Sihag BK, Prajapati R, Singh T, et al. Metoprolol vs ivabradine in patients with mitral stenosis in sinus rhythm. Int J Cardiol. 2016;221:562–6.CrossRef Agrawal V, Kumar N, Lohiya B, Sihag BK, Prajapati R, Singh T, et al. Metoprolol vs ivabradine in patients with mitral stenosis in sinus rhythm. Int J Cardiol. 2016;221:562–6.CrossRef
21.
Zurück zum Zitat Muhammad F, Nazeer A, Rehman Z. The comparison of effects of ivabradine and atenolol on heart rate and symptoms in patients with mild-to-moderate mitral stenosis. Pak J Med Health Sci. 2016;10(2):345–7. Muhammad F, Nazeer A, Rehman Z. The comparison of effects of ivabradine and atenolol on heart rate and symptoms in patients with mild-to-moderate mitral stenosis. Pak J Med Health Sci. 2016;10(2):345–7.
22.
Zurück zum Zitat Rajesh GN, Sajeer K, Sajeev CG, Bastian C, Vinayakumar D, Muneer K, et al. A comparative study of ivabradine and atenolol in patients with moderate mitral stenosis in sinus rhythm. Indian Heart J. 2016;68(3):311–5.CrossRef Rajesh GN, Sajeer K, Sajeev CG, Bastian C, Vinayakumar D, Muneer K, et al. A comparative study of ivabradine and atenolol in patients with moderate mitral stenosis in sinus rhythm. Indian Heart J. 2016;68(3):311–5.CrossRef
23.
Zurück zum Zitat Saggu DK, Narain VS, Dwivedi SK, Sethi R, Chandra S, Puri A, et al. Effect of ivabradine on heart rate and duration of exercise in patients with mild-to-moderate mitral stenosis: a randomized comparison with metoprolol. J Cardiovasc Pharmacol. 2015;65(6):552.CrossRef Saggu DK, Narain VS, Dwivedi SK, Sethi R, Chandra S, Puri A, et al. Effect of ivabradine on heart rate and duration of exercise in patients with mild-to-moderate mitral stenosis: a randomized comparison with metoprolol. J Cardiovasc Pharmacol. 2015;65(6):552.CrossRef
24.
Zurück zum Zitat Parakh N, Chaturvedi V, Kurian S, Tyagi S. Effect of ivabradine vs atenolol on heart rate and effort tolerance in patients with mild to moderate mitral stenosis and normal sinus rhythm. J Card Fail. 2012;18(4):282–8.CrossRef Parakh N, Chaturvedi V, Kurian S, Tyagi S. Effect of ivabradine vs atenolol on heart rate and effort tolerance in patients with mild to moderate mitral stenosis and normal sinus rhythm. J Card Fail. 2012;18(4):282–8.CrossRef
25.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.CrossRef Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.CrossRef
26.
Zurück zum Zitat Higgins J. Green S. Cochrane handbook for systematic reviews of interventions Version 5.1. 0. The Cochrane Collaboration. Confidence intervals. 2011. Higgins J. Green S. Cochrane handbook for systematic reviews of interventions Version 5.1. 0. The Cochrane Collaboration. Confidence intervals. 2011.
27.
Zurück zum Zitat Otto CM, Gaasch W, Yeon S. Clinical Manifestations and diagnosis of rheumatic mitral stenosis. UpToDate, Post, TW. 2018. Otto CM, Gaasch W, Yeon S. Clinical Manifestations and diagnosis of rheumatic mitral stenosis. UpToDate, Post, TW. 2018.
28.
Zurück zum Zitat Mardikar H, Sahasrabhojaney V, Jalgaonkar P, Mahorkar U, Mardikar M, Waghmare B. Long term effects of atenolol in patients of mitral stenosis and normal sinus rhythm. Indian J Med Res. 1995;101:25–7.PubMed Mardikar H, Sahasrabhojaney V, Jalgaonkar P, Mahorkar U, Mardikar M, Waghmare B. Long term effects of atenolol in patients of mitral stenosis and normal sinus rhythm. Indian J Med Res. 1995;101:25–7.PubMed
29.
Zurück zum Zitat Manz M, Reuter M, Lauck G, Omran H, Jung W. A single intravenous dose of ivabradine, a novel If inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology. 2003;100(3):149–55.CrossRef Manz M, Reuter M, Lauck G, Omran H, Jung W. A single intravenous dose of ivabradine, a novel If inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology. 2003;100(3):149–55.CrossRef
30.
Zurück zum Zitat Pasceri E, Curcio A, Achille F, de Serio D, Zinzi S, Torella D. Acute reduction of transmitral gradient after I (f) channel inhibition in patients with mitral valve stenosis or a mitral annuloplasty ring [Abst 974]. Europace. 2009;11(Suppl 2):S6. Pasceri E, Curcio A, Achille F, de Serio D, Zinzi S, Torella D. Acute reduction of transmitral gradient after I (f) channel inhibition in patients with mitral valve stenosis or a mitral annuloplasty ring [Abst 974]. Europace. 2009;11(Suppl 2):S6.
31.
Zurück zum Zitat Borer JS, Fox K, Jaillon P, Lerebours G. Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107(6):817–23.CrossRef Borer JS, Fox K, Jaillon P, Lerebours G. Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107(6):817–23.CrossRef
32.
Zurück zum Zitat López-Bescós L, Filipova S, Martos R. Long-term safety and efficacy of ivabradine in patients with chronic stable angina. Cardiology. 2007;108(4):387–96.CrossRef López-Bescós L, Filipova S, Martos R. Long-term safety and efficacy of ivabradine in patients with chronic stable angina. Cardiology. 2007;108(4):387–96.CrossRef
33.
Zurück zum Zitat Tardif J-C, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of ivabradine, a new selective I f inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26(23):2529–36.CrossRef Tardif J-C, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of ivabradine, a new selective I f inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26(23):2529–36.CrossRef
34.
Zurück zum Zitat Ye L, Ke D, Chen Q, Li G, Deng W, Wu Z. Effectiveness of ivabradine in treating stable angina pectoris. Medicine. 2016;95(14):e3245. Ye L, Ke D, Chen Q, Li G, Deng W, Wu Z. Effectiveness of ivabradine in treating stable angina pectoris. Medicine. 2016;95(14):e3245.
Metadaten
Titel
Comparative efficacy of ivabradine versus beta-blockers in patients with mitral stenosis in sinus rhythm: systematic review and meta-analysis
verfasst von
Nashmil Ghadimi
Sara Kaveh
Hossein Shabaninejad
Alaadine Lijassi
Ali Zahed Mehr
Hossein Hosseinifard
Publikationsdatum
18.01.2019
Verlag
Springer International Publishing
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 1/2019
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-018-00778-z

Weitere Artikel der Ausgabe 1/2019

International Journal of Clinical Pharmacy 1/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.